{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:44:07Z","timestamp":1783068247835,"version":"3.54.6"},"reference-count":92,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaci.2021.07.005","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T07:09:02Z","timestamp":1630652942000},"page":"661-667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Safety of anti-TNF agents in pregnancy"],"prefix":"10.1016","volume":"148","author":[{"given":"Kara M.","family":"De Felice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2021.07.005_bib1","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cgh.2020.01.028","article-title":"Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century","volume":"18","author":"Ananthakrishnan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib2","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/art.21577","article-title":"Incidence and prevalence of ankylosing spondylitis in Northern Norway","volume":"53","author":"Bakland","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2021.07.005_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1053\/berh.2002.0257","article-title":"Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome","volume":"16","author":"Symmons","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/j.1572-0241.2007.01355.x","article-title":"Disease activity in pregnant women with Crohn\u2019s disease and birth outcomes: a regional Danish cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2340\/00015555-2923","article-title":"Effect of maternal psoriasis on pregnancy and birth outcomes: a population-based cohort study from Denmark and Sweden","volume":"98","author":"Br\u00f6ms","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaci.2021.07.005_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/acr.23924","article-title":"Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis","volume":"72","author":"Smith","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2021.07.005_bib8","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2021.07.005_bib9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2021.07.005_bib10","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.2174\/138161211798157658","article-title":"Anti-TNF treatment in rheumatoid arthritis","volume":"17","author":"Geiler","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jaci.2021.07.005_bib11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00296-014-3006-2","article-title":"Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety","volume":"34","author":"Lemos","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaci.2021.07.005_bib12","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jaci.2021.07.005_bib13","article-title":"TNF-alpha inhibitors for ankylosing spondylitis","author":"Maxwell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaci.2021.07.005_bib14","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","article-title":"Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis","volume":"76","author":"Burmester","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn\u2019s disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaci.2021.07.005_bib18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2021.07.005_bib21","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/rheumatology\/keq185","article-title":"Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding","volume":"49","author":"Berthelsen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2021.07.005_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib23","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2021.07.005_bib24","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1097\/MIB.0000000000001123","article-title":"Inadequate gestational weight gain, the hidden link between maternal IBD and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study","volume":"23","author":"Bengtson","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib25","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s10620-017-4547-5","article-title":"Inadequate gestational weight gain predicts adverse pregnancy outcomes in mothers with inflammatory bowel disease: results from a prospective US pregnancy cohort","volume":"62","author":"Bengtson","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaci.2021.07.005_bib26","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/00054725-200105000-00011","article-title":"Inflammatory bowel disease and pregnancy","volume":"7","author":"Katz","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.25.1.52","article-title":"Crohn\u2019s disease and pregnancy","volume":"25","author":"Khosla","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2021.07.005_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/gut.21.6.469","article-title":"Ulcerative colitis and pregnancy","volume":"21","author":"Willoughby","year":"1980","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2021.07.005_bib29","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/apt.12412","article-title":"The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women","volume":"38","author":"Pedersen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/apt.12417","article-title":"Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease","volume":"38","author":"Abhyankar","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3899\/jrheum.180226","article-title":"Does rheumatoid arthritis really improve during pregnancy? A\u00a0systematic review and metaanalysis","volume":"46","author":"Jethwa","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib32","first-page":"355","article-title":"Women with inflammatory polyarthritis have babies of lower birth weight","volume":"28","author":"Bowden","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib33","doi-asserted-by":"crossref","unstructured":"Mokbel A, Lawson DO, Farrokhyar F. Pregnancy outcomes in women with ankylosing spondylitis: a scoping literature and methodological review [published online ahead of print January 19, 2021]. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05588-9.","DOI":"10.1007\/s10067-021-05588-9"},{"key":"10.1016\/j.jaci.2021.07.005_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13075-017-1269-1","article-title":"Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients","volume":"19","author":"van den Brandt","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib35","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/acr.23747","article-title":"Psoriatic arthritis disease activity during and after pregnancy: a prospective multicenter study","volume":"71","author":"Ursin","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2021.07.005_bib36","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archderm.141.5.601","article-title":"Hormonal effect on psoriasis in pregnancy and post partum","volume":"141","author":"Murase","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib37","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1468-3083.2010.03917.x","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis","volume":"25","author":"Cohen-Barak","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.07.005_bib38","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.2310\/7750.2009.00024","article-title":"Psoriasis comorbidities","volume":"13","author":"Guenther","year":"2009","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2021.07.005_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1365-2133.2010.09899.x","article-title":"Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis","volume":"163","author":"Bandoli","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.24037","article-title":"Mediation of adverse pregnancy outcomes in autoimmune conditions by pregnancy complications: a mediation analysis of autoimmune conditions and adverse pregnancy outcomes","volume":"72","author":"Bandoli","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jaci.2021.07.005_bib41","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1002\/ddr.21199","article-title":"A possible role of polycystic ovary syndrome for pregnancy complications in women with psoriasis","volume":"75","author":"De Simone","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.jaci.2021.07.005_bib42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.14547","article-title":"Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies","volume":"175","author":"Bobotsis","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2010.02.005","article-title":"Psoriasis and pregnancy outcomes: a nationwide population-based study","volume":"64","author":"Yang","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib44","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/jcph.374","article-title":"Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice","volume":"55","author":"Vande Casteele","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.jaci.2021.07.005_bib45","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/apt.14040","article-title":"The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease","volume":"45","author":"Seow","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib46","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2021.07.005_bib47","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1136\/ard.2008.105924","article-title":"Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant\u2019s serum","volume":"68","author":"Murashima","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib49","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A\u00a0retrospective cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740330903578639","article-title":"A safety assessment of tumor necrosis factor antagonists during pregnancy","volume":"9","author":"Osting","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaci.2021.07.005_bib51","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib52","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib53","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib54","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/1741-7015-11-174","article-title":"Safety of TNF-\u03b1 inhibitors during IBD pregnancy: a systematic review","volume":"11","author":"Nielsen","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.jaci.2021.07.005_bib55","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib56","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","article-title":"Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Narula","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib57","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v19.i17.2591","article-title":"Tumor necrosis factor-\u03b1 inhibitor therapy and fetal risk: a systematic literature review","volume":"19","author":"Marchioni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib58","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib59","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-year TREAT registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib60","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/00365521.2015.1079924","article-title":"Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation","volume":"51","author":"Bortlik","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib61","first-page":"1456","article-title":"Outcome of elective withdrawal of anti-tumour necrosis factor-\u03b1 therapy in patients with Crohn\u2019s disease in established remission","volume":"11","author":"Brooks","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2021.07.005_bib62","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib63","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"de Lima","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jaci.2021.07.005_bib64","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2018.12.022","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American Gastroenterological Association IBD Parenthood Project Working Group","volume":"156","author":"Mahadevan","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2021.07.005_bib65","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2015.12.003","article-title":"The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy","volume":"150","author":"Nguyen","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2021.07.005_bib66","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.jaci.2021.07.005_bib67","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/rheumatology\/kel400","article-title":"Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy","volume":"46","author":"Roux","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2021.07.005_bib68","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jbspin.2008.04.016","article-title":"Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature","volume":"76","author":"Berthelot","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaci.2021.07.005_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00393-010-0652-y","article-title":"Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment [in German]","volume":"69","author":"Rump","year":"2010","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib70","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib71","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-020-01376-y","article-title":"Intrauterine exposure to biologics in inflammatory autoimmune diseases: a systematic review","volume":"80","author":"Ghalandari","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jaci.2021.07.005_bib72","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaci.2021.07.005_bib73","article-title":"Pregnancy outcomes in women exposed to etanercept: the OTIS Autoimme Diseases in Pregnancy Project","volume":"58","author":"Johnson","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaci.2021.07.005_bib74","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/art.41191","article-title":"2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000262284","article-title":"Treatment of psoriasis with anti-TNF drugs during\u00a0pregnancy: case report and review of the literature","volume":"220","author":"Puig","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2021.07.005_bib76","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ad.2016.09.004","article-title":"A case series of patients with psoriasis exposed to biologic therapy during pregnancy: the BIOBADADERM Register and a review of the literature","volume":"108","author":"Echeverr\u00eda-Garc\u00eda","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaci.2021.07.005_bib77","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/jamadermatol.2020.5595","article-title":"Pregnancy outcomes in women with moderate-to-severe psoriasis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"157","author":"Kimball","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib78","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1111\/jdv.15671","article-title":"Psoriasis and pregnancy outcomes in biological therapies: a real-life, multi-centre experience","volume":"33","author":"Odorici","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2021.07.005_bib79","doi-asserted-by":"crossref","first-page":"401.e1","DOI":"10.1016\/j.jaad.2013.09.010","article-title":"Safety of dermatologic medications in pregnancy and lactation, part I: pregnancy","volume":"70","author":"Murase","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib80","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/1203475420928376","article-title":"Management of plaque psoriasis with biologic therapies in women of child-bearing potential consensus paper","volume":"24","author":"Yeung","year":"2020","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2021.07.005_bib81","doi-asserted-by":"crossref","first-page":"243","DOI":"10.14309\/ajg.0000000000000910","article-title":"Biologics during pregnancy in women with inflammatory bowel disease and risk of infantile infections: a systematic review and meta-Analysis","volume":"116","author":"Gubatan","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib82","doi-asserted-by":"crossref","unstructured":"Long MD, Siegel CA, Abraham BP, Chiorean M, Mahadevan U. Day care attendance and infectious complications in children born to mothers with inflammatory bowel disease [published online ahead of print February 4, 2021]. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2021.02.003.","DOI":"10.1016\/j.cgh.2021.02.003"},{"key":"10.1016\/j.jaci.2021.07.005_bib83","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/apt.15971","article-title":"Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy","volume":"52","author":"Br\u00f6ms","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaci.2021.07.005_bib84","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/00365521.2014.920913","article-title":"Self-reported\u00a0adherence to medical treatment, breastfeeding behaviour, and disease activity\u00a0during the postpartum period in women with Crohn\u2019s disease","volume":"49","author":"Julsgaard","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib85","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2021.07.005_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2021.07.005_bib87","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ajg.2010.464","article-title":"The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: pregnancy and pediatrics","volume":"106","author":"Mahadevan","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaci.2021.07.005_bib88","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/rheumatology\/kev404","article-title":"BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding, part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids","volume":"55","author":"Flint","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaci.2021.07.005_bib89","doi-asserted-by":"crossref","first-page":"417.e1","DOI":"10.1016\/j.jaad.2013.09.009","article-title":"Safety of dermatologic medications in pregnancy and lactation, part II: lactation","volume":"70","author":"Butler","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn\u2019s disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2021.07.005_bib91","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jaci.2021.07.005_bib92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921011234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674921011234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:31:25Z","timestamp":1758792685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674921011234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":92,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0091674921011234"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2021.07.005","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of anti-TNF agents in pregnancy","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2021.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}